在线咨询 skype
New compound MM41 shrinks pancreatic cancer tumour
author: anonymous [ 2015-06-27 20:27:45 ]

Recently, Scientists from UCL have developed a new compound MM41, can block the defective gene, it can reduce pancreatic tumor growth in mice by 80%. MM41 can target DNA in subsection (tetrads), which is different from the normal quadruplex DNA, specifically only in the presence of a defect gene.

The researchers conducted a small-scale test in mice, a pancreatic cancer model they will be two groups of mice, each group of eight, different doses (12 different dose) MM41 therapy twice a week for a period of 40 days. The control group without any treatment. MM41 highest dose in the treatment group, the mean reduction in tumor size by 80%, and in 30 days after treatment, the tumor that mice no longer continue to grow. Moreover, MM41 highest dose group, two mice pancreatic tumors completely disappeared, and in the next 239 days (the natural life roughly mice), no recurrence occurred. In addition, the researchers found that in this study, MM41 no significant side effects, and MM41 to other tissues and organs intact, the mice did not lose weight on.

The study also found that, MM41 tumor cells can enter the nucleus of the k-RAS and BCL-2 significantly inhibited the two genes, both genetic abnormalities present in most pancreatic tumors. BCL-2 gene may regulate apoptosis. In many of the cancers, BCL-2 expression levels have increased, and thus contribute to tumor cell survival. However, MM41 can inhibit BCL-2, ultimately causing cancer cells to apoptosis. The study was conducted in mouse models of pancreatic cancer conducted in the future, researchers will further optimize this compound to enter clinical trials, providing new treatment options to patients with pancreatic cancer.

Request PDF of the origin paper, pls send email to

Address: No. 2799, Fengzhe Road, Fengxian District, Shanghai, China. Zip Code: 201407 E-mail:  Sitemap XML